TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02507219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: On the day of sessions 2-4, subjects will receive either placebo, 200 mg of ibuprofen or 600 mg of ibuprofen after signing the consent form for this study in a randomized, double-blind, counter balanced order. Each study session will occur 1-2 weeks following the previous session. Ibuprofen will be capsuled, and identical placebo capsules will be produced.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: On the day of sessions 2-4, subjects will receive either placebo, 200 mg of ibuprofen or 600 mg of ibuprofen after signing the consent form for this study in a randomized, double-blind, counter balanced order. Each study session will occur 1-2 weeks following the previous session. Ibuprofen will be capsuled, and identical placebo capsules will be produced.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: On the day of sessions 2-4, subjects will receive either placebo, 200 mg of ibuprofen or 600 mg of ibuprofen after signing the consent form for this study in a randomized, double-blind, counter balanced order. Each study session will occur 1-2 weeks following the previous session. Ibuprofen will be capsuled, and identical placebo capsules will be produced.
Study: NCT04581239

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active neural mobilization
Description: Active neural mobilization Base line treatment followed heating pad 10 minutes, lumber traction with 50 %of body weight in accordance with tolerance. 15 to 20 Lumber segmental mobilization.~Active oscillatory nerve mobilization was given in 3 sets of 10 repetition in each set with 20 sec rest time between set

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: passive neural mobilization
Description: Base line treatment followed heating pad 10 minutes, lumber traction with 50 %of body weight in accordance with tolerance. 15 to 20 Lumber segmental mobilization~Passive neural mobilization This oscillatory nerve mobilization was given in 3 sets of 10 repetition in each set with 20 sec rest time between set. Both groups received total 18 session 3 session per week for consecutive 6 weeks
Study: NCT04234568

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Dotatate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triapine
Description: Given PO
Study: NCT01120028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus: target trough levels 6-12 ng/mL for first 6-months after maintenance therapy randomization, then 5-10 ng/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus: target trough levels 6-12 ng/mL for first 6-months after maintenance therapy randomization, then 5-10 ng/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus: target trough levels 5-7 ng/mL after maintenance therapy randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus: target trough levels 5-7 ng/mL after maintenance therapy randomization.
Study: NCT03947658

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical crown lengthening
Description: Surgical lengthening of teeth with short clinical crown and prosthetic rehabilitation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical crown lengthening
Description: Surgical lengthening of teeth with short clinical crown and prosthetic rehabilitation
Study: NCT02699866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLT Implant Ø 2.9 mm
Description: Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.
Study: NCT03701451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Demethylated drug decitabine
Description: Induced treatment by demethylating drug decitabine 7mg/m2 d1-5 and cisplatin 80mg/m2 d1 for 3 cycles to regionally advanced nasopharyngeal carcinoma followed by concurrent chemoradiotherapy with cisplatin 80mg/m2 d1 for 3 cycles.
Study: NCT01491464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS/INTER FIX™
Description: The INTER FIX™ device containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone/INTER FIX™
Description: The INTER FIX™ device containing autogenous bone taken from the patient's iliac crest.
Study: NCT03095781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL888
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT02579577

Intervention type: OTHER
Intervention: Observation
Description: Observation of clinic appointments and ward rounds if the child is admitted to hospital during the study period.

Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured interviews will be conducted approximately 3 times during the study period with each participant.

Intervention type: OTHER
Intervention: Medical notes review
Description: The child's electronic medical record will be accessed periodically to identify any planned appointments or periods of hospitalisation and their medical notes will also be reviewed at the end of the study.
Study: NCT04257461

Intervention type: DRUG
Group type: OTHER
Intervention: Fluoropyrimidine
Description: Monotherapy: 12 cycles of 5FU or 8 cycles of Capecitabine. The choice of fluoropyrimidine must be specified prior to randomisation.

Intervention type: DRUG
Group type: OTHER
Intervention: Fluoropyrimidine
Description: Monotherapy: 12 cycles of 5FU or 8 cycles of Capecitabine. The choice of fluoropyrimidine must be specified prior to randomisation.

Intervention type: DRUG
Group type: OTHER
Intervention: Fluoropyrimidine
Description: Monotherapy: 12 cycles of 5FU or 8 cycles of Capecitabine. The choice of fluoropyrimidine must be specified prior to randomisation.
Study: NCT04636580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent accompanying the child during treatment
Description: After the parents were divided into two groups, anxious and non-anxious, the groups were equally divided randomly and the parents accompanied their children during the treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent accompanying the child during treatment
Description: After the parents were divided into two groups, anxious and non-anxious, the groups were equally divided randomly and the parents accompanied their children during the treatment
Study: NCT03794544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV will be administered Q4W (on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV will be administered Q4W (on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV will be administered Q4W (on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV will be administered Q4W (on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab 3000 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Monalizumab 750 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Danvatirsen
Description: Danvatirsen 200 mg IV will be administered on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period) and later every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
Study: NCT01386645

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low glycemic index (LGI) diet
Description: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index \<35) for 4 weeks with all food provided by the Human Nutrition Lab

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: high glycemic index (HGI) diet plus placebo (PLAC)
Description: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index \>70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
Study: NCT00442286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rheos® Baroreflex Hypertension System
Description: Electrical activation of the Carotid Baroreflex

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rheos® Baroreflex Hypertension System
Description: Electrical activation of the Carotid Baroreflex
Study: NCT04997967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine/Propofol
Description: The level of sedation was assessed at 1-3 min intervals, and the infusion rate was adjusted accordingly to achieve a Ramsay Sedation Scale (RSS) score of 5. Any movement of the patient was treated by increasing infusion rate and the infusion was discontinued at the end of the procedure. The total propofol consumed was calculated and the recovery time was recorded and calculated as the time from discontinuation of infusion of the study drug till achievement of RSS score of 3. Then patients were discharged to post-anesthesia care unit (PACU) after attaining an Aldrete Recovery Scale Score of 9- 10 \[19\]. Time taken to achieve this score was also recorded.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Sedation was initially started by bolus dose of 0.5 mg/kg propofol IV over 3 minutes then, infusion was started at the rate of 50 µg /kg/min till RSS score of 5.
Study: NCT02659644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral L-citrulline
Description: There will be a total of 16 patients divided into 4 equal cohorts. The first 4 cohorts will be started on a 7 day oral regimen of twice daily L-citrulline. They will return to clinic on day #7 to evaluate nitric oxide metabolite levels and pharmacokinetic (PK) profile of citrulline. After PK analysis, the next cohort of patients will be given a higher or lower dose based on their weight and also based safety and tolerability. Of note, a PK analysis will be performed for each 4 patient cohort prior to starting citrulline for the subsequent cohort. Assessment for adverse events will be done at specified times throughout the study duration via both phone and clinic encounters.
Study: NCT03564054

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Participants on this arm will be treated with photodynamic therapy. PDT is a two-stage process. The first stage of PDT is the intravenous injection of porfimer sodium (Photofrin) administered as a single slow intravenous injection over 3 to 5 minutes. The second stage involves the application of laser light to the tumor by bronchoscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Argon Plasma Coagulation
Description: Participants on this arm will be treated with argon plasma coagulation. A flexible probe housing a wire delivers high-frequency, high-voltage electric current to a monopolar tungsten electrode present at the tip of the probe. Argon gas flows through the probe, and is charged or ionized to produce plasma as it flows around the tungsten electrode. Electric current flows through the plasma to the nearest tissue, and heat is produced as it passes through the tissue. Increased resistance created by coagulated tissue impairs the flow of electric current, and keeps the ablation depth to 1 to 2 mm.
Study: NCT00075803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Fluconazole will be administered orally once daily. Fluconazole capsules should be taken at least one hour before or one hour after a meal. If oral drug is not possible, it will be given intravenously once daily in a total volume of 200 mL in patients \> 12 years. For adults, each 200 mL infusion will be administered over 2 hours. In patients \< 12 years, intravenous doses will be prepared.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Voriconazole will be administered orally twice daily. Voriconazole capsules should be taken at least one hour before or one hour after a meal. Taken concomitantly with food, bioavailability of voriconazole is reduced. If oral drug is not possible, it will be given intravenously at a dosage of 200 mg every 12 hours over two hours in patients \> 12 years. Each voriconazole dose will be diluted to a total volume of 200 mL in patients \> 12 years. Volumes of the formulation required to provide 4 mg/kg doses for children age \< 12 years.
Study: NCT01743274

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCT
Description: Optical Coherence Tomography (OCT) is a recent imaging modality that yields cross-sectional images with a resolution 10 times greater than that of intravascular ultrasound (IVUS). OCT uses a near-infra-red light source to obtain images of the interior walls of the coronary arteries and is increasingly used to evaluate vulnerable atherosclerotic plaques and assess placement and response to stenting.~OCT images are acquired by automated pullback over 2 to 3 seconds of the light source that yields a helicoidal image of a longitudinal segment of 50 mm. Intravascular imaging is obtained by injecting contrast medium or saline solution.
Study: NCT02006043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib 150mg
Study: NCT04578028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2808
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2808
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2808
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2808
Description: Investigational drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug
Study: NCT01134211

Intervention type: DEVICE
Group type: OTHER
Intervention: nelfilcon A
Description: Commercially marketed, single-vision, soft contact lens for daily disposable wear
Study: NCT01386645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high glycemic index diet plus N-acetylcysteine
Description: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index \>70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
Study: NCT00484328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: different dosing regimes of Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: different dosing regimes of Ribavirin
Study: NCT02410200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Study: NCT04250259

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets of placebo in the morning before breakfast and one tablet of placebo in the evening before dinner for 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAMe 400 mg tablet
Description: SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months
Study: NCT04257461

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: Bichemotherapy: Oxaliplatine combined with Fluoropyrimidine.
Study: NCT01134211

Intervention type: DEVICE
Group type: OTHER
Intervention: nelfilcon A
Description: Commercially marketed, single-vision, soft contact lens for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: filcon II 3
Description: Commercially marketed, single-vision, soft contact lens for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: filcon II 3
Description: Commercially marketed, single-vision, soft contact lens for daily disposable wear
Study: NCT02521519

Intervention type: OTHER
Group type: OTHER
Intervention: Medial branch block in one side
Description: MBB: Using sterile conditions, 25G needles will be placed in the desired position. In its final position for the L3 and L4 vertebrae the needle tip should reside at the junction of the superior articular process and the transverse process. At the L5-S1 level the needle tip should reach the junction between the sacral ala and the superior articular process of S1. Following a negative aspiration 0.5ml of injectate will be injected into each site.
Study: NCT02521519

Intervention type: OTHER
Group type: OTHER
Intervention: paravertebral deep intramuscular (PDI) injection
Description: injections will target the deep para-spinal muscles between the spinous process and inter-pedicular line of the L3-5 vertebrae. Under fluoroscopic guidance, a 25-gauge needle will be advanced, directed towards the lamina at the mid-distance between inter-pedicular line and the spinous process of the L3, L4 and L5 vertebrae, until touching the bone. A straight forceps will be attached to the junction of the skin and the needle; the needle will then be withdrawn by 1.4cm, to reside inside the muscle bulk. A five ml syringe diameter will be used to point 1.4 cm withdrawal. Following a negative blood aspiration, each level will be injected with 0.5 ml of the injectate.
Study: NCT03756649

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: 50 ml will be collected

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: 50 ml will be collected

Intervention type: PROCEDURE
Intervention: Urine Collection
Description: 50 ml will be collected

Intervention type: PROCEDURE
Intervention: Urine Collection
Description: 50 ml will be collected

Intervention type: PROCEDURE
Intervention: Stool Collection
Description: Three 25 ml tubes will be collected
Study: NCT04733482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cosmetic care
Study: NCT03756649

Intervention type: PROCEDURE
Intervention: Stool Collection
Description: Three 25 ml tubes will be collected
Study: NCT03580720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory threshold loading protocol
Description: Subjects will be instrumented with catheters that measure electrical activity of the diaphragm and transdiaphragmatic pressure. Subjects will perform a stepwise inspiratory threshold loading protocol to induce a wide range of diaphragm activity.
Study: NCT05609058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dedicated treatment board with no degree
Description: the patients were placed in the prone position on a dedicated treatment board with no degree incline using an arm support (with both arms above the head). Te board contained an open aperture on one side to allow for the ipsilateral breast to hang freely away from the chest wall
Study: NCT02018315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Triheptanoin is a 7-carbon medium chain triglyceride
Study: NCT01473511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strongest Families Intervention (formerly Family Help)
Description: Distance HEALTH education intervention focussed on skill learning for parents
Study: NCT04595695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transparent mask
Description: A transparent mask worn by the surgeons in customary fashion will be used.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Typical surgical covered mask
Description: A standard covered surgical mask worn by the surgeons in in customary fashion will be used.
Study: NCT01725997

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hook plate
Description: Surgery with hook plate followed by physiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Patients will be following a program specific for AC joint dislocations
Study: NCT03073005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based Mastery Learning (SBML)
Description: The SBML training group will first 1) watch the VAD video, then 2) participate in a SBML intervention using the simulator for a) driveline exit site sterile dressing changes; b) performing controller self-tests; c) changing power sources; d) troubleshooting emergent VAD-related malfunction; and e) recognizing specific signs and symptoms requiring immediate contact with the VAD team.
Study: NCT00720083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: Given orally

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Patients undergo radiotherapy 5 times a week for up to 6.5 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiotherapy 5 times a week for up to 6.5 weeks.